EMC2 and paraganglioma: For RFS, BLCA and HNSC patients with high EMC2 expression levels showed poor prognoses, while KIRC and pheochromocytoma and paraganglioma (PCPG) patients with high EMC2 expression levels had better prognostic survival (Figure 2B).